Perry M Elliott

List of Publications by Citations

440 papers	50,835 citations	96 h-index	222 g-index
527 ext. papers	62,633 ext. citations	6.8 avg, IF	7.11 L-index

#	Paper	IF	Citations
440	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European Journal of Heart Failure*, **2016**, 18, 891-975	12.3	4036
439	ESC Guidelines for the diagnosis and management of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *European Heart Journal*, **2012**, 33, 1787-847	9.5	3691
438	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). *European Heart Journal*, **2014**, 35, 2733-79	9.5	2361
437	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *European Heart Journal*, **2008**, 29, 2388-442	9.5	2298
436	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). *European Heart Journal*, **2015**, 36, 2793-2867	9.5	2187
435	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. *European Journal of Heart Failure*, **2012**, 14, 803-69	12.3	1892
434	Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2008**, 29, 270-6	9.5	1641
433	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2013**, 34, 2636-48, 2648a-2648d	9.5	1552
432	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *European Heart Journal*, **2013**, 34, 2281-329	9.5	1491
431	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). *European Journal of Heart Failure*, **2008**, 10, 933-89	12.3	1355
430	Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *New England Journal of Medicine*, **2018**, 379, 1007-1016	59.2	859
429	2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). *Europace*, **2013**, 15, 1070-118	3.9	731
428	Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. *Journal of the American College of Cardiology*, **2000**, 36, 2212-8	15.1	712
427	2018 ESC Guidelines for the diagnosis and management of syncope. *European Heart Journal*, **2018**, 39, 1883-1948	9.5	672
426	Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. *Circulation*, **2010**, 122, 138-44	16.7	662
425	Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. *Journal of the American College of Cardiology*, **2003**, 41, 1561-7	15.1	614
424	Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2010**, 56, 867-74	15.1	599

423	A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). *European Heart Journal*, **2014**, 35, 2010-20	9.5	570
422	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. *European Heart Journal*, **2016**, 37, 1850-8	9.5	473
421	Hypertrophic cardiomyopathy. *Lancet, The*, **2004**, 363, 1881-91	40	437
420	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology	3.9	426
419	Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. *Circulation*, **2002**, 105, 1407-11	16.7	424
418	Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. *Journal of the American College of Cardiology*, **2003**, 42, 2014-27	15.1	416
417	Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. *Journal of the American College of Cardiology*, **2003**, 42, 873-9	15.1	370
416	Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. *Lancet, The*, **2001**, 357, 420-4	40	364
415	Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. *Journal of the American College of Cardiology*, **2012**, 59, 493-500	15.1	353
414	Natural history and familial characteristics of isolated left ventricular non-compaction. *European Heart Journal*, **2005**, 26, 187-92	9.5	344
413	Atlas of the clinical genetics of human dilated cardiomyopathy. *European Heart Journal*, **2015**, 36, 1123-35a	9.5	334
412	Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2010**, 31, 2715-26	9.5	324
411	Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. *European Heart Journal*, **2003**, 24, 2151-5	9.5	312
410	Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. *Circulation: Cardiovascular Imaging*, **2013**, 6, 392-8	3.9	310
409	Diagnosis of left-ventricular non-compaction in patients with left-ventricular systolic dysfunction: time for a reappraisal of diagnostic criteria?. *European Heart Journal*, **2008**, 29, 89-95	9.5	302
408	Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. *European Heart Journal*, **2006**, 27, 1933-41	9.5	273
407	2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. *European Heart Journal*, **2021**, 42, 17-96	9.5	264
406	How to develop a more accurate risk prediction model when there are few events. *BMJ, The*, **2015**, 351, h3868	5.9	258

405	Prospective evaluation of relatives for familial arrhythmogenic right ventricular cardiomyopathy/dysplasia reveals a need to broaden diagnostic criteria. *Journal of the American College of Cardiology*, **2002**, 40, 1445-50	15.1	257
404	Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2013**, 34, 1448-58	9.5	246
403	Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. *European Heart Journal*, **2007**, 28, 1228-35	9.5	244
402	Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2005**, 45, 1251-8	15.1	242
401	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. *Journal of Clinical Investigation*, **2003**, 111, 209-216	15.9	230
400	Physiologic limits of left ventricular hypertrophy in elite junior athletes: relevance to differential diagnosis of athlete© heart and hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2002**, 40, 1431-6	15.1	225
399	Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. *Heart*, **2012**, 98, 1436-41	5.1	221
398	Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. *Circulation*, **2010**, 122, 1562-9	16.7	215
397	Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. *Molecular Genetics and Metabolism*, **2003**, 80, 207-15	3.7	215
396	Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. *Circulation*, **2017**, 135, 1357-1377	16.7	214
395	Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. *Circulation*, **2001**, 104, 1380-4	16.7	214
394	Enzyme replacement therapy with agalsidase alfa in patients with Fabry© disease: an analysis of registry data. *Lancet, The*, **2009**, 374, 1986-96	40	212
393	Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey. *Journal of Medical Genetics*, **2009**, 46, 548-52	5.8	206
392	Relation between myocyte disarray and outcome in hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2001**, 88, 275-9	3	201
391	Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. *Journal of the American College of Cardiology*, **2004**, 44, 2033-40	15.1	192
390	Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. *Circulation*, **1997**, 96, 2987-91	16.7	190
389	Improved imputation of low-frequency and rare variants using the UK10K haplotype reference panel. *Nature Communications*, **2015**, 6, 8111	17.4	186
388	Electrocardiographic changes in 1000 highly trained junior elite athletes. *British Journal of Sports Medicine*, **1999**, 33, 319-24	10.3	183

387	Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy. *European Heart Journal*, **2012**, 33, 1128-36	9.5	182
386	Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **1999**, 33, 1596-601	15.1	176
385	Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. *Heart*, **2014**, 100, 465-72	5.1	172
384	Familial evaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics and revised task force criteria. *Circulation*, **2011**, 123, 2701-9	16.7	168
383	Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. *Circulation*, **2006**, 113, 356-64	16.7	167
382	Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput sequencing. *Journal of Medical Genetics*, **2013**, 50, 228-39	5.8	160
381	The heart in Anderson-Fabry disease and other lysosomal storage disorders. *Heart*, **2007**, 93, 528-35	5.1	155
380	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2020**, 396, 759-769	40	149
379	Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. *Heart*, **2008**, 94, 1478-84	5.1	148
378	Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. *American Journal of Cardiology*, **2005**, 96, 842-6	3	147
377	Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. *Heart*, **2008**, 94, 1288-94	5.1	146
376	Whole-genome sequencing of patients with rare diseases in a national health system. *Nature*, **2020**, 583, 96-102	50.4	139
375	Evolving concepts in dilated cardiomyopathy. *European Journal of Heart Failure*, **2018**, 20, 228-239	12.3	135
374	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *European Heart Journal*, **2021**, 42, 3427-3520	9.5	134
373	Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. *Journal of the American College of Cardiology*, **2007**, 49, 2419-26	15.1	131
372	Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study. *Journal of the American Society of Nephrology: JASN*, **2017**, 28, 1631-1641	12.7	130
371	Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2009**, 2, 436-41		129
370	The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. *Journal of Cardiovascular Magnetic Resonance*, **2006**, 8, 479-82	6.9	128

369	A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. *Heart*, **2013**, 99, 1800-11	5.1	126
368	Prevalence of desmosomal protein gene mutations in patients with dilated cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2010**, 3, 314-22		125
367	Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. *Europace*, **2010**, 12, 313-21	3.9	125
366	Adenosine monophosphate-activated protein kinase disease mimicks hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome: natural history. *Journal of the American College of Cardiology* , **2005**, 45, 922-30	15.1	125
365	Quantification of left ventricular trabeculae using fractal analysis. *Journal of Cardiovascular Magnetic Resonance*, **2013**, 15, 36	6.9	123
364	Exercise-induced ventricular arrhythmias and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. *European Heart Journal*, **2009**, 30, 2599-605	9.5	123
363	Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*, **2014**, 16, 99	6.9	122
362	The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy. *Heart*, **2012**, 98, 116-25	5.1	122
361	Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. *Heart*, **2011**, 97, 1957-60	5.1	122
360	Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. *Circulation*, **2007**, 115, 76-83	16.7	122
359	Prevalence and clinical significance of cardiovascular abnormalities in patients with the LEOPARD syndrome. *American Journal of Cardiology*, **2007**, 100, 736-41	3	121
358	Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *European Heart Journal*, **2014**, 35, 2279-84	9.5	114
357	Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. *Heart*, **2014**, 100, 1851-8	5.1	114
356	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. *Journal of Clinical Investigation*, **2003**, 111, 209-16	15.9	114
355	Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. *Annals of Internal Medicine*, **2005**, 143, 108-15	8	111
354	Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis. *European Heart Journal*, **2020**, 41, 1414-1429	9.5	110
353	Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. *Journal of the American College of Cardiology*, **2000**, 36, 864-70	15.1	107
352	Germline selection shapes human mitochondrial DNA diversity. *Science*, **2019**, 364,	33.3	105

351	Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2004**, 44, 2315-25	15.1	104
350	Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. A comparison of clinical, haemodynamic and exercise outcomes. *European Heart Journal*, **2002**, 23, 1617-24	9.5	104
349	A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. *Heart*, **2013**, 99, 534-41	5.1	103
348	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. *JACC: Heart Failure*, **2019**, 7, 709-716	7.9	97
347	Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. *European Journal of Heart Failure*, **2013**, 15, 376-84	12.3	97
346	Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2000**, 86, 162-8	3	97
345	International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). *Circulation*, **2018**, 137, 1015-1023	16.7	95
344	Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome. *Circulation: Cardiovascular Genetics*, **2012**, 5, 156-66		94
343	Gu□ ESC 2016 sobre el diagn□tico y tratamiento de la insuficiencia cardiaca aguda y cr□nica. *Revista Espanola De Cardiologia*, **2016**, 69, 1167.e1-1167.e85	1.5	91
342	Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. *International Journal of Cardiology*, **2014**, 177, 400-8	3.2	90
341	Novel genotype-phenotype associations demonstrated by high-throughput sequencing in patients with hypertrophic cardiomyopathy. *Heart*, **2015**, 101, 294-301	5.1	89
340	Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease. *European Journal of Heart Failure*, **2010**, 12, 114-21	12.3	89
339	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. *European Heart Journal*, **2017**, 38, 2649-2662	9.5	88
338	Prevalence of J-point elevation in sudden arrhythmic death syndrome families. *Journal of the American College of Cardiology*, **2011**, 58, 286-90	15.1	87
337	Pathogenesis of cardiotoxicity induced by anthracyclines. *Seminars in Oncology*, **2006**, 33, S2-7	5.5	86
336	Practical Instructions for the 2018 ESC Guidelines for the diagnosis and management of syncope. *European Heart Journal*, **2018**, 39, e43-e80	9.5	83
335	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, **2020**, 76, e159-e240	15.1	82
334	CMR detects abnormal septal convexity into the left ventricle in preclinical hypertrophic cardiomyopathy. *Journal of Cardiovascular Magnetic Resonance*, **2015**, 17,	6.9	78

333	It's not just the mitral valve - abnormal motion of the whole aorto-mitral apparatus occurs in both overt and subclinical hypertrophic cardiomyopathy. *Journal of Cardiovascular Magnetic Resonance*, **2016**, 18,	6.9	78
332	Interstitial expansion in health and disease - an equilibrium contrast CMR study. *Journal of Cardiovascular Magnetic Resonance*, **2012**, 14,	6.9	78
331	Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. *Journal of Clinical Investigation*, **2003**, 111, 925-925	15.9	78
330	Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). *European Journal of Heart Failure*, **2015**, 17, 837-45	12.3	77
329	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, **2020**, 142, e558-e631	16.7	77
328	Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene. *Circulation: Cardiovascular Genetics*, **2012**, 5, 10-7		75
327	Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. *European Heart Journal Cardiovascular Imaging*, **2018**, 19, 757-767	4.1	74
326	European expert consensus statement on therapeutic goals in Fabry disease. *Molecular Genetics and Metabolism*, **2018**, 124, 189-203	3.7	71
325	Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding Protein-12. *Molecular Genetics and Metabolism*, **2004**, 82, 162-6	3.7	71
324	Lamin and the heart. *Heart*, **2018**, 104, 468-479	5.1	70
323	Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study. *Heart*, **2011**, 97, 1744-52	5.1	69
322	Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). *JAMA Cardiology*, **2019**, 4, 918-927	16.2	67
321	Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. *European Journal of Heart Failure*, **2008**, 10, 3-13	12.3	66
320	Development and Validation of a New Risk Prediction Score for Life-Threatening Ventricular Tachyarrhythmias in Laminopathies. *Circulation*, **2019**, 140, 293-302	16.7	63
319	Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy. *Journal of the American College of Cardiology*, **2002**, 39, 455-62	15.1	63
318	Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis. *European Journal of Preventive Cardiology*, **2017**, 24, 1220-1230	3.9	62
317	Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. *European Heart Journal*, **2013**, 34, 802-8	9.5	62
316	Anderson-Fabry disease and the heart. *Progress in Cardiovascular Diseases*, **2010**, 52, 326-35	8.5	62

315	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, **2020**, 142, e533-e557	16.7	61
314	The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. *Molecular Genetics and Metabolism Reports*, **2019**, 19, 100454	1.8	61
313	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. *European Heart Journal*, **2018**, 39, 1784-1793	9.5	60
312	QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **1998**, 82, 1514-9	3	60
311	Transmural myocardial blood flow distribution in hypertrophic cardiomyopathy and effect of treatment. *Basic Research in Cardiology*, **1999**, 94, 49-59	11.8	60
310	Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Heart*, **2016**, 102, 1533-43	5.1	60
309	Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. *Heart*, **2007**, 93, 372-4	5.1	59
308	Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. *European Heart Journal*, **2013**, 34, 2529-37	9.5	58
307	Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. *American Heart Journal*, **1998**, 136, 972-81	4.9	58
306	The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the European Society of Human Genetics. *European Heart Journal*, **2015**, 36, 1367-70	9.5	57
305	Abnormal cardiac formation in hypertrophic cardiomyopathy: fractal analysis of trabeculae and preclinical gene expression. *Circulation: Cardiovascular Genetics*, **2014**, 7, 241-8		57
304	Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy. *Journal of the American College of Cardiology*, **2004**, 44, 398-405	15.1	56
303	Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2014**, 7, 863-71	3.9	55
302	Dilated Cardiomyopathy Due´to´BLC2-Associated Athanogene´3´(BAG3)´Mutations. *Journal of the American College of Cardiology*, **2018**, 72, 2471-2481	15.1	53
301	Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease. *Heart*, **2015**, 101, 961-6	5.1	51
300	Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors. *PLoS ONE*, **2017**, 12, e0182379	3.7	51
299	Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2015**, 8, 1022-31	7.6	50
298	Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. *Europace*, **2011**, 13, 1781-8	3.9	50

297	Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. *European Heart Journal*, **1996**, 17, 1056-64	9.5	50
296	Diagnostic yield of molecular autopsy in patients with sudden arrhythmic death syndrome using targeted exome sequencing. *Europace*, **2016**, 18, 888-96	3.9	49
295	Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial). *Circulation: Heart Failure*, **2017**, 10,	7.6	48
294	Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. *European Journal of Heart Failure*, **2008**, 10, 507-13	12.3	48
293	Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report. *European Journal of Heart Failure*, **2019**, 21, 955-964	12.3	47
292	Sudden cardiac death in hypertrophic cardiomyopathy. *Circulation: Arrhythmia and Electrophysiology*, **2013**, 6, 443-51	6.4	47
291	Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. *European Heart Journal Cardiovascular Imaging*, **2020**, 21, 326-336	4.1	46
290	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. *Heart*, **2017**, 103, 672-678	5.1	43
289	Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. *American Journal of Cardiology*, **2013**, 111, 111-7	3	43
288	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. *European Heart Journal*, **2016**, 37, 164-73	9.5	42
287	Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy. Relationship to clinical presentation and outcome. *European Heart Journal*, **1998**, 19, 500-7	9.5	42
286	Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. *Journal of Medical Genetics*, **2018**, 55, 351-358	5.8	41
285	A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. *Cardiovascular Pathology*, **2010**, 19, 293-301	3.8	41
284	Left ventricular strain and untwist in hypertrophic cardiomyopathy: relation to exercise capacity. *American Heart Journal*, **2010**, 159, 825-32	4.9	41
283	Plasma immunoreactive endothelin concentration correlates with severity of coronary artery disease in patients with stable angina pectoris and normal ventricular function. *Journal of the American College of Cardiology*, **1996**, 28, 14-9	15.1	41
282	How should hypertrophic cardiomyopathy be classified?: What's in a name? Dilemmas in nomenclature characterizing hypertrophic cardiomyopathy and left ventricular hypertrophy. *Circulation: Cardiovascular Genetics*, **2009**, 2, 81-5; discussion 86		40
281	Angina pectoris and normal coronary arteriograms: clinical presentation and hemodynamic characteristics. *American Journal of Cardiology*, **1995**, 76, 35D-42D	3	39
280	Mitochondrial diseases and the heart: an overview of molecular basis, diagnosis, treatment and clinical course. *Future Cardiology*, **2012**, 8, 71-88	1.3	38

279	Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2006**, 98, 515-9	3	38
278	Evidence From Family Studies for Autoimmunity in Arrhythmogenic Right Ventricular Cardiomyopathy: Associations of Circulating Anti-Heart and Anti-Intercalated Disk Autoantibodies With Disease Severity and Family History. *Circulation*, **2020**, 141, 1238-1248	16.7	37
277	Imaging phenotype versus genotype in hypertrophic cardiomyopathy. *Circulation: Cardiovascular Imaging*, **2011**, 4, 156-68	3.9	37
276	Fractal Analysis of Myocardial Trabeculations in 2547 Study Participants: Multi-Ethnic Study of Atherosclerosis. *Radiology*, **2015**, 277, 707-15	20.5	35
275	Diagnosis of apical hypertrophic cardiomyopathy: T-wave inversion and relative but not absolute apical left ventricular hypertrophy. *International Journal of Cardiology*, **2015**, 183, 143-8	3.2	34
274	100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. *New England Journal of Medicine*, **2021**, 385, 1868-1880	59.2	34
273	An expert consensus document on the management of cardiovascular manifestations of Fabry disease. *European Journal of Heart Failure*, **2020**, 22, 1076-1096	12.3	33
272	Recurrent missense mutations in TMEM43 (ARVD5) due to founder effects cause arrhythmogenic cardiomyopathies in the UK and Canada. *European Heart Journal*, **2013**, 34, 1002-11	9.5	33
271	Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. *Europace*, **2010**, 12, 1156-75	3.9	33
270	The relation of ventricular arrhythmia electrophysiological characteristics to cardiac phenotype and circadian patterns in hypertrophic cardiomyopathy. *Europace*, **2012**, 14, 724-33	3.9	33
269	The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - A systematic literature review by a European panel of experts. *Molecular Genetics and Metabolism*, **2019**, 126, 224-235	3.7	33
268	Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. *Journal of the American College of Cardiology*, **2018**, 72, 2457-2467	15.1	33
267	Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. *ESC Heart Failure*, **2019**, 6, 1041-1051	3.7	32
266	A straightforward guide to the sarcomeric basis of cardiomyopathies. *Heart*, **2014**, 100, 1916-23	5.1	32
265	The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2008**, 51, 2058-61	15.1	32
264	Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. *Journal of Interventional Cardiac Electrophysiology*, **2002**, 6, 482-6		32
263	Arrhythmic Genotypes in Familial Dilated Cardiomyopathy: Implications for Genetic Testing and Clinical Management. *Heart Lung and Circulation*, **2019**, 28, 31-38	1.8	32
262	Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy. *International Journal of Cardiology*, **2020**, 299, 186-191	3.2	32

261	Genetics of heart failure. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 2451-61	6.9	31
260	Left ventricular noncompaction. *Current Opinion in Cardiology*, **2009**, 24, 209-13	2.1	31
259	Isolated left ventricular non-compaction: the case for abnormal myocardial development. *Cardiology in the Young*, **2007**, 17, 124-9	1	31
258	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, **2020**, 76, 3022-3055	15.1	31
257	Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. *JAMA Cardiology*, **2019**, 4, 230-235	16.2	30
256	2015 ESC Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 176	0.7	30
255	Dynamic electrocardiographic changes in patients with arrhythmogenic right ventricular cardiomyopathy. *Heart*, **2010**, 96, 516-22	5.1	30
254	Mutations in PDLIM3 and MYOZ1 encoding myocyte Z line proteins are infrequently found in idiopathic dilated cardiomyopathy. *Molecular Genetics and Metabolism*, **2007**, 90, 435-40	3.7	30
253	Dilated cardiomyopathy: a genetically heterogeneous disease. *Lancet, The*, **2002**, 360, 654-5	40	30
252	Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. *Journal of the American College of Cardiology*, **2020**, 76, 550-559	15.1	30
251	Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 1075-1093	4.1	29
250	Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives. *Circulation*, **2019**, 140, 184-192	16.7	28
249	The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. *Molecular Genetics and Metabolism*, **2019**, 126, 212-223	3.7	28
248	Mortality Among Referral Patients With Hypertrophic Cardiomyopathy vs the General European Population. *JAMA Cardiology*, **2020**, 5, 73-80	16.2	28
247	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. *Revista Espanola De Cardiologia*, **2012**, 65, 938.e1-938.e59	1.5	27
246	Extracellular matrix turnover and disease severity in Anderson-Fabry disease. *Journal of Inherited Metabolic Disease*, **2007**, 30, 88-95	5.4	27
245	Prevalence of F-fluorodeoxyglucose positron emission tomography abnormalities in patients with arrhythmogenic right ventricular cardiomyopathy. *International Journal of Cardiology*, **2019**, 284, 99-104	3.2	27
244	Prevention of sudden cardiac death in hypertrophic cardiomyopathy. *Heart*, **2014**, 100, 254-60	5.1	26

243	Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease. *Journal of the American College of Cardiology*, **2011**, 58, 88-9	15.1	26
242	Loss-of-function desmoplakin I and II mutations underlie dominant arrhythmogenic cardiomyopathy with a hair and skin phenotype. *British Journal of Dermatology*, **2019**, 180, 1114-1122	4	26
241	Cardiac Involvement in Fabry Disease: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2021**, 77, 922-936	15.1	26
240	Fractal frontiers in cardiovascular magnetic resonance: towards clinical implementation. *Journal of Cardiovascular Magnetic Resonance*, **2015**, 17, 80	6.9	25
239	Use of high-throughput targeted exome-sequencing to screen for copy number variation in hypertrophic cardiomyopathy. *European Journal of Medical Genetics*, **2015**, 58, 611-6	2.6	25
238	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. *Revista Portuguesa De Cardiologia*, **2018**, 37, 1-10	1	25
237	Cardiomyopathy as presenting sign of glycogenin-1 deficiency-report of three cases and review of the literature. *Journal of Inherited Metabolic Disease*, **2017**, 40, 139-149	5.4	25
236	Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy. *European Heart Journal*, **2006**, 27, 3073; author reply 3073-4	9.5	25
235	A targeted metabolomics assay for cardiac metabolism and demonstration using a mouse model of dilated cardiomyopathy. *Metabolomics*, **2016**, 12, 59	4.7	25
234	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Revista Espanola De Cardiologia (English Ed)*, **2014**, 67, 58	0.7	24
233	The classification concept of the ESC Working Group on myocardial and pericardial diseases for dilated cardiomyopathy. *Herz*, **2007**, 32, 446-51	2.6	24
232	Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the Gene. *Circulation: Heart Failure*, **2020**, 13, e006832	7.6	24
231	Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy. *Circulation: Arrhythmia and Electrophysiology*, **2017**, 10,	6.4	23
230	Quantitative expression of the mutated lamin A/C gene in patients with cardiolaminopathy. *Journal of the American College of Cardiology*, **2012**, 60, 1916-20	15.1	23
229	The embryological basis of subclinical hypertrophic cardiomyopathy. *Scientific Reports*, **2016**, 6, 27714	4.9	23
228	Takotsubo is not a cardiomyopathy. *International Journal of Cardiology*, **2018**, 254, 250-253	3.2	23
227	Epidemiology and Clinical Aspects of Genetic Cardiomyopathies. *Heart Failure Clinics*, **2018**, 14, 119-128	3.3	22
226	Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation. *PLoS ONE*, **2018**, 13, e0193550	3.7	22

225	A novel Myosin essential light chain mutation causes hypertrophic cardiomyopathy with late onset and low expressivity. *Biochemistry Research International*, **2012**, 2012, 685108	2.4	22
224	European Society of Cardiology: cardiovascular disease statistics 2021.. *European Heart Journal*, **2022**,	9.5	22
223	Risk Stratification for Sudden Cardiac Death in Non-Ischaemic Dilated Cardiomyopathy. *Current Cardiology Reports*, **2019**, 21, 155	4.2	22
222	Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. *Heart*, **2019**, 105, 623-631	5.1	22
221	Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy. *Heart*, **2017**, 103, 300-306	5.1	21
220	DPD Quantification in Cardiac´Amyloidosis: A Novel Imaging Biomarker. *JACC: Cardiovascular Imaging*, **2020**, 13, 1353-1363	8.4	21
219	Classification of cardiomyopathies: evolution or revolution?. *Journal of the American College of Cardiology*, **2013**, 62, 2073-4	15.1	21
218	Fabry International Prognostic Index: a predictive severity score for Anderson-Fabry disease. *Journal of Medical Genetics*, **2012**, 49, 212-20	5.8	21
217	Late-onset hypertrophic cardiomyopathy caused by a mutation in the cardiac troponin T gene. *New England Journal of Medicine*, **1999**, 341, 1855-6	59.2	21
216	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2018**, 11, e001974	5.2	21
215	Pregnancy and its management in women with GSD type III - a single centre experience. *Journal of Inherited Metabolic Disease*, **2012**, 35, 245-51	5.4	20
214	Takotsubo cardiomyopathy: do the genetics matter?. *Heart Failure Clinics*, **2013**, 9, 207-16, ix	3.3	20
213	T wave complexity in patients with hypertrophic cardiomyopathy. *PACE - Pacing and Clinical Electrophysiology*, **1998**, 21, 2382-6	1.6	20
212	Genes and disease expression in hypertrophic cardiomyopathy. *Lancet, The*, **1998**, 352, 1162-3	40	20
211	Dual chamber pacing in hypertrophic cardiomyopathy: long-term effects on diastolic function. *PACE - Pacing and Clinical Electrophysiology*, **2002**, 25, 1433-40	1.6	20
210	The genetics of hypertrophic cardiomyopathy. *Global Cardiology Science & Practice*, **2018**, 2018, 36	0.7	20
209	Left ventricular hypertrophy caused by a novel nonsense mutation in FHL1. *European Journal of Medical Genetics*, **2013**, 56, 251-5	2.6	19
208	Prevalence of sequence variants in the RAS-mitogen activated protein kinase signaling pathway in pre-adolescent children with hypertrophic cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2012**, 5, 317-26		19

207	Cardiovascular Complications of Neuromuscular Disorders. *Current Treatment Options in Cardiovascular Medicine*, **2002**, 4, 171-179	2.1	19
206	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet, The*, **2021**, 397, 2467-2475	40	19
205	Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. *JACC: Heart Failure*, **2021**, 9, 115-123	7.9	19
204	Improving Interpretation of Cardiac Phenotypes and Enhancing Discovery With Expanded Knowledge in the Gene Ontology. *Circulation Genomic and Precision Medicine*, **2018**, 11, e001813	5.2	19
203	Anderson-Fabry disease in heart failure. *Biophysical Reviews*, **2018**, 10, 1107-1119	3.7	19
202	Identification of a Multiplex Biomarker Panel for Hypertrophic Cardiomyopathy Using Quantitative Proteomics and Machine Learning. *Molecular and Cellular Proteomics*, **2020**, 19, 114-127	7.6	18
201	Genetics and metabolic cardiomyopathies. *Herz*, **2012**, 37, 598-610	2.6	17
200	Mutations in the cardiac Troponin C gene are a cause of idiopathic dilated cardiomyopathy in childhood. *Cardiology in the Young*, **2007**, 17, 675-7	1	17
199	Reversal of inappropriate peripheral vascular responses in hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, **2005**, 46, 883-92	15.1	17
198	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. *European Journal of Heart Failure*, **2021**, 23, 895-905	12.3	17
197	Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. *Journal of the American College of Cardiology*, **2020**, 76, 186-197	15.1	16
196	Images in cardiovascular medicine. Cardiovascular magnetic resonance of isolated left ventricular apical hypoplasia. *Circulation*, **2008**, 117, e504-5	16.7	16
195	Sex-related differences in cardiomyopathies. *International Journal of Cardiology*, **2019**, 286, 239-243	3.2	16
194	Proteomic Analysis of the Myocardium in Hypertrophic Obstructive Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2018**, 11,	5.2	16
193	Abnormal septal convexity into the left ventricle occurs in subclinical hypertrophic cardiomyopathy. *Journal of Cardiovascular Magnetic Resonance*, **2015**, 17, 64	6.9	15
192	Genetic biomarkers in hypertrophic cardiomyopathy. *Biomarkers in Medicine*, **2013**, 7, 505-16	2.3	14
191	The role of endomyocardial biopsy in the management of cardiovascular disease: a commentary on joint AHA/ACC/ESC guidelines. *Heart*, **2009**, 95, 759-60	5.1	14
190	Sudden death in athletes. *Clinical Medicine*, **2012**, 12, 253-6	1.9	14

189	The 2006 American Heart Association classification of cardiomyopathies is not the gold standard. *Circulation: Heart Failure*, **2008**, 1, 77-9; discussion 80	7.6	14
188	Is QT dispersion associated with sudden cardiac death in patients with hypertrophic cardiomyopathy?. *Annals of Noninvasive Electrocardiology*, **2001**, 6, 209-15	1.5	14
187	The Portuguese Registry of Hypertrophic Cardiomyopathy: Overall results. *Revista Portuguesa De Cardiologia (English Edition)*, **2018**, 37, 1-10	0	13
186	Inverted U-Shaped Relation Between the Risk of Sudden Cardiac Death and Maximal Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy. *Circulation: Arrhythmia and Electrophysiology*, **2016**, 9,	6.4	13
185	Left ventricular outflow tract obstruction caused by accessory mitral valve tissue. *Journal of the American Society of Echocardiography*, **2006**, 19, 354.e5-354.e8	5.8	13
184	Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records. *PLoS ONE*, **2018**, 13, e0191214	3.7	13
183	Dilated cardiomyopathy: so many cardiomyopathies!. *European Heart Journal*, **2020**, 41, 3784-3786	9.5	13
182	Community delivery of semiautomated fractal analysis tool in cardiac mr for trabecular phenotyping. *Journal of Magnetic Resonance Imaging*, **2017**, 46, 1082-1088	5.6	12
181	Cardiac output response and peripheral oxygen extraction during exercise among symptomatic hypertrophic cardiomyopathy patients with and without left ventricular outflow tract obstruction. *Heart*, **2014**, 100, 639-46	5.1	12
180	135 Novel Hybrid Positron Emission Tomography - Magnetic Resonance (PET-MR) Multi-modality Inflammatory Imaging has Improved Diagnostic Accuracy for Detecting Cardiac Sarcoidosis. *Heart*, **2014**, 100, A80.1-A80	5.1	12
179	The influence of aortoseptal angulation on provocable left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Open Heart*, **2014**, 1, e000176	3	12
178	The molecular genetics of hypertrophic cardiomyopathy: prognostic implications. *Europace*, **2000**, 2, 4-14	3.9	12
177	Prognosis and prognostic factors in node-negative cervix cancer. *International Journal of Gynecological Cancer*, **1996**, 6, 477-482	3.5	12
176	Long-term outcomes for different surgical strategies to treat left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *European Journal of Heart Failure*, **2018**, 20, 398-405	12.3	12
175	Arrhythmogenic cardiomyopathies (ACs): diagnosis, risk stratification and management. *Heart*, **2019**, 105, 1117-1128	5.1	11
174	Right ventricular cardiomyopathies: a multidisciplinary approach to diagnosis. *Echocardiography*, **2015**, 32 Suppl 1, S75-94	1.5	11
173	Guí ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevenciñ de la muerte sñbita cardiaca. *Revista Espanola De Cardiologia*, **2016**, 69, 176.e1-176.e77	1.5	11
172	Heart rate recovery in patients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2014**, 113, 1011-7	3	11

171	New approaches to the clinical diagnosis of inherited heart muscle disease. *Heart*, **2013**, 99, 1451-61	5.1	11
170	Pacing in hypertrophic cardiomyopathy. *Cardiology Clinics*, **2000**, 18, 67-79, viii	2.5	11
169	Myectomy plus Alfieri technique for outflow tract obstruction in hypertrophic cardiomyopathy. *Circulation*, **2010**, 122, 938-9	16.7	10
168	Current applications of biomarkers in cardiomyopathies. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 825-37	2.5	9
167	Mutations in cause an autosomal-recessive form of hypertrophic cardiomyopathy. *Heart*, **2020**, 106, 1342-1348	5.1	9
166	Clinical utility gene card for: hypertrophic cardiomyopathy (type 1-14). *European Journal of Human Genetics*, **2011**, 19,	5.3	9
165	Current management of hypertrophic cardiomyopathy. *Current Treatment Options in Cardiovascular Medicine*, **2008**, 10, 496-504	2.1	9
164	Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.. *Circulation: Heart Failure*, **2021**, CIRCHEARTFAILURE120008193	7.6	9
163	Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a contemporary reappraisal. *EuroIntervention*, **2019**, 15, 411-417	3.1	9
162	The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	9
161	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of Thoracic and Cardiovascular Surgery*, **2021**, 162, e23-e106	1.5	9
160	Why systematic literature reviews in Fabry disease should include all published evidence. *European Journal of Medical Genetics*, **2019**, 62, 103702	2.6	8
159	Cryptic Splice-Altering Variants in Are a Prevalent Cause of Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002905	5.2	8
158	Improved Diagnosis of Rare Disease Patients through Systematic Detection of Runs of Homozygosity. *Journal of Molecular Diagnostics*, **2020**, 22, 1205-1215	5.1	8
157	A microRNA Expression Profile as Non-Invasive Biomarker in a Large Arrhythmogenic Cardiomyopathy Cohort. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	8
156	ST segment "hump" during exercise testing and the risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. *Annals of Noninvasive Electrocardiology*, **2009**, 14, 158-64	1.5	8
155	Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy. *Journal of Cardiovascular Medicine*, **2006**, 7, 711-3	1.9	8
154	Can the assessment of dynamic QT dispersion on exercise electrocardiogram predict sudden cardiac death in hypertrophic cardiomyopathy?. *PACE - Pacing and Clinical Electrophysiology*, **2000**, 23, 1953-6	1.6	8

153	Prognosis of idiopathic dilated cardiomyopathy. *Journal of Cardiac Failure*, **1995**, 1, 337-45	3.3	8
152	Arrhythmogenic Cardiomyopathy: A Disease or Merely a Phenotype?. *European Cardiology Review*, **2020**, 15, 1-5	3.9	8
151	2015 ESC GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH VENTRICULAR ARRHYTHMIAS AND THE PREVENTION OF SUDDEN CARDIAC DEATH. *Russian Journal of Cardiology*, **2016**, 5-86	1.3	8
150	Cadherin 2-Related Arrhythmogenic Cardiomyopathy: Prevalence and Clinical Features. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003097	5.2	8
149	Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 3063-3073	9.5	8
148	Clinical and genetic characterization of patients with hypertrophic cardiomyopathy and right atrial enlargement. *Journal of Cardiovascular Medicine*, **2017**, 18, 249-254	1.9	7
147	Isolated aortic root dilation in homocystinuria. *Journal of Inherited Metabolic Disease*, **2018**, 41, 109-115	5.4	7
146	Assessment of a conduction-repolarisation metric to predict Arrhythmogenesis in right ventricular disorders. *International Journal of Cardiology*, **2018**, 271, 75-80	3.2	7
145	Management of aortic stenosis in mucopolysaccharidosis type I. *International Journal of Cardiology*, **2014**, 172, e430-1	3.2	7
144	Evolution and clinical importance of fibrosis in HCM. *JACC: Cardiovascular Imaging*, **2011**, 4, 1221-3	8.4	7
143	Subclinical skeletal muscle abnormalities in patients with hypertrophic cardiomyopathy and their relation to clinical characteristics. *International Journal of Cardiology*, **2003**, 89, 249-56	3.2	7
142	A case of infective endocarditis in a farmer caused by Streptococcus equinus. *European Heart Journal*, **1993**, 14, 1292-3	9.5	7
141	The Novel Desmin Variant p.Leu115Ile Is Associated With a Unique Form of Biventricular Arrhythmogenic Cardiomyopathy. *Canadian Journal of Cardiology*, **2021**, 37, 857-866	3.8	7
140	Prevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy. *European Journal of Heart Failure*, **2021**, 23, 1276-1286	12.3	7
139	Association of Left Ventricular Systolic Dysfunction Among Carriers of Truncating Variants in Filamin C With Frequent Ventricular Arrhythmia and End-stage Heart Failure. *JAMA Cardiology*, **2021**, 6, 891-901	16.2	7
138	Hypertrophic cardiomyopathy. *JAMA - Journal of the American Medical Association*, **1999**, 282, 2302-3	27.4	7
137	Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.. *Journal of the American College of Cardiology*, **2021**, 78, 2518-2532	15.1	7
136	Prevalence of variants detected by whole-exome sequencing in hypertrophic cardiomyopathy. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2019**, 26, 243-247	2.7	6

135	Almanac 2014: cardiomyopathies. *Heart*, **2014**, 100, 756-64	5.1	6
134	The 2014 ESC Guidelines on the Diagnosis and Management of Hypertrophic Cardiomyopathy have been published. *European Heart Journal*, **2014**, 35, 2849-50	9.5	6
133	Non-invasive assessment of cardiac output at rest and during exercise by finger plethysmography. *Clinical Physiology and Functional Imaging*, **2013**, 33, 338-43	2.4	6
132	Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS). *Value in Health*, **2011**, 14, 862-6	3.3	6
131	The science of uncertainty and the art of probability: syncope and its consequences in hypertrophic cardiomyopathy. *Circulation*, **2009**, 119, 1697-9	16.7	6
130	Mechanisms and medical management of exercise intolerance in hypertrophic cardiomyopathy. *Current Pharmaceutical Design*, **2015**, 21, 466-72	3.3	6
129	Diagnostic Clues for the Diagnosis of Nonsarcomeric Hypertrophic Cardiomyopathy (Phenocopies): Amyloidosis, Fabry Disease, and Mitochondrial Disease. *Journal of Cardiovascular Echography*, **2018**, 28, 120-123	0.6	6
128	Left Atrial Volume during Stress Is Associated with Increased Risk of Arrhythmias in Patients with Hypertrophic Cardiomyopathy. *Journal of Cardiovascular Echography*, **2019**, 29, 1-6	0.6	6
127	Atrial fibrillation, anticoagulation management and risk of stroke in the Cardiomyopathy/Myocarditis registry of the EURObservational Research Programme of the European Society of Cardiology. *ESC Heart Failure*, **2020**, 7, 3601	3.7	6
126	2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. *Europace*, **2021**,	3.9	6
125	Identification, clinical manifestation and structural mechanisms of mutations in AMPK associated cardiac glycogen storage disease. *EBioMedicine*, **2020**, 54, 102723	8.8	5
124	Deletions of specific exons of FHOD3 detected by next-generation sequencing are associated with hypertrophic cardiomyopathy. *Clinical Genetics*, **2020**, 98, 86-90	4	5
123	Individualized surgical strategies for left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *European Journal of Cardio-thoracic Surgery*, **2018**, 53, 1237-1243	3	5
122	Outcomes following the surgical management of left ventricular outflow tract obstruction; A systematic review and meta-analysis. *International Journal of Cardiology*, **2018**, 265, 62-70	3.2	5
121	Therapeutic goals in Fabry disease: Recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy. *Molecular Genetics and Metabolism*, **2019**, 126, 210-211	3.7	5
120	94 Percutaneous Mitral Repair in Hypertrophic Cardiomyopathy. *Heart*, **2014**, 100, A54-A55	5.1	5
119	Early and medium-term outcomes of Alfieri mitral valve repair in the management of systolic anterior motion during septal myectomy. *Journal of Cardiac Surgery*, **2017**, 32, 686-690	1.3	5
118	Genetic aspects and investigation of sudden death in young people. *Clinical Medicine*, **2008**, 8, 607-10	1.9	5

117	External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy. *European Journal of Preventive Cardiology*, **2021**,	3.9	5
116	Corrigendum to: 2018 ESC Guidelines for the diagnosis and management of syncope. *European Heart Journal*, **2018**, 39, 2002	9.5	5
115	The structural effects of mutations can aid in differential phenotype prediction of beta-myosin heavy chain (Myosin-7) missense variants. *Bioinformatics*, **2016**, 32, 2947-55	7.2	4
114	Psychosocial adjustment and quality of life in children undergoing screening in a specialist paediatric hypertrophic cardiomyopathy clinic. *Cardiology in the Young*, **2016**, 26, 961-7	1	4
113	Improving the diagnostic accuracy for detecting cardiac sarcoidosis. *Expert Review of Cardiovascular Therapy*, **2015**, 13, 223-36	2.5	4
112	Guía de práctica clínica de la ESC 2014 sobre el diagnóstico y manejo de la miocardiopatía hipertrófica. *Revista Espanola De Cardiologia*, **2015**, 68, 63.e1-63.e52	1.5	4
111	How should hypertrophic cardiomyopathy be classified?: Molecular diagnosis for hypertrophic cardiomyopathy: Not ready for prime time. *Circulation: Cardiovascular Genetics*, **2009**, 2, 87-9; discussion 89		4
110	Right ventricular hypertrabeculation associated with double-outlet left ventricle: exaggeration of a normal pattern or right ventricular cardiomyopathy?. *Journal of Cardiovascular Medicine*, **2010**, 11, 193-5	1.9	4
109	Syncope and ventricular arrhythmias in hypertrophic cardiomyopathy are not related to the derangement of coronary microvascular function. *European Heart Journal*, **1997**, 18, 1946-50	9.5	4
108	Optimization of concomitant medication in Fabry cardiomyopathy. *Acta Paediatrica, International Journal of Paediatrics*, **2007**, 96, 81-3	3.1	4
107	Hypertrophic cardiomyopathy: a 50th anniversary. Preface. *Heart*, **2008**, 94, 1247-8	5.1	4
106	The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. *Current Cardiology Reports*, **2001**, 3, 167-72	4.2	4
105	Tissue Doppler features of cardiac amyloidosis. *Clinical Cardiology*, **2000**, 23, 701	3.3	4
104	Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a European observational multicentre study. *Europace*, **2021**, 23, 1409-1417	3.9	4
103	Contemporary and Future Approaches to Precision Medicine in Inherited Cardiomyopathies: JACC Focus Seminar 3/5. *Journal of the American College of Cardiology*, **2021**, 77, 2551-2572	15.1	4
102	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. *ESC Heart Failure*, **2021**, 8, 95-105	3.7	4
101	CardioScape mapping the cardiovascular funding landscape in Europe. *European Heart Journal*, **2018**, 39, 2423-2430	9.5	4
100	A Family History of Sudden Death Should Not Be a Primary Indication for an Implantable Cardioverter Defibrillator in Hypertrophic Cardiomyopathy. *Canadian Journal of Cardiology*, **2015**, 31, 1407-9	3.8	3

99	Biventricular pacemaker therapy improves exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy via augmented diastolic filling on exercise. *European Journal of Heart Failure*, **2020**, 22, 1263-1272	12.3	3
98	Rare Disease in Cardiovascular Medicine I. *European Heart Journal*, **2017**, 38, 1625-1628	9.5	3
97	Rare Diseases in Cardiovascular Medicine II. *European Heart Journal*, **2017**, 38, 1629-1631	9.5	3
96	Risk stratification in hypertrophic cardiomyopathy: time for renewal?. *Journal of Cardiovascular Medicine*, **2013**, 14, 319-25	1.9	3
95	Enzyme replacement therapy for Fabry□s disease □Authors□reply. *Lancet, The*, **2010**, 375, 1523-1524	40	3
94	Beyond sudden death in the athlete: how to identify family members at risk. *British Journal of Sports Medicine*, **2011**, 45, 189-92	10.3	3
93	Acute myocardial ischemia associated with latent left ventricular outflow tract obstruction in the absence of left ventricular hypertrophy. *Journal of the American Society of Echocardiography*, **2007**, 20, 772.e1-4	5.8	3
92	The prevention of sudden death in hypertrophic cardiomyopathy. *Expert Opinion on Pharmacotherapy*, **2002**, 3, 499-504	4	3
91	Natural history of hypertrophic cardiomyopathy. *Current Cardiology Reports*, **2000**, 2, 141-7	4.2	3
90	Sudden death and hypertrophic cardiomyopathy. *Lancet, The*, **2001**, 357, 1975-1976	40	3
89	Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics.. *European Heart Journal*, **2022**,	9.5	3
88	Epidemiology of cardiomyopathies and incident heart failure in a population-based cohort study.. *Heart*, **2021**,	5.1	3
87	Hidden in Heart Failure. *European Cardiology Review*, **2019**, 14, 89-96	3.9	3
86	ESC EORP Cardiomyopathy Registry: real-life practice of genetic counselling and testing in adult cardiomyopathy patients. *ESC Heart Failure*, **2020**, 7, 3013-3021	3.7	3
85	The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM. *Cardiovascular Research*, **2020**, 116, e175-e178	9.9	3
84	Diagnostic Impact of Repeated Expert Review & Long-Term Follow-Up in Determining Etiology of Idiopathic Cardiac Arrest. *Journal of the American Heart Association*, **2021**, 10, e019610	6	3
83	Sudden cardiac death in inherited cardiomyopathy. *International Journal of Cardiology*, **2017**, 237, 56-59	3.2	2
82	Takotsubo: One, no one and one hundred thousand diseases. *International Journal of Cardiology*, **2018**, 261, 35	3.2	2

81	Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease. *Future Cardiology*, **2017**, 13, 521-527	1.3	2
80	Restrictive cardiomyopathy and hypertrophic cardiomyopathy overlap: the importance of the phenotype. *Neurology International*, **2012**, 2, 10	0	2
79	The quantification and role of diffuse myocardial fibrosis in familial dilated cardiomyopathy - an equilibrium contrast cmr study. *Journal of Cardiovascular Magnetic Resonance*, **2011**, 13,	6.9	2
78	A case of transient hypertrophic cardiomyopathy. *Postgraduate Medical Journal*, **2010**, 86, 310-2	2	2
77	Hypertrophic Cardiomyopathy. *Cardiac Electrophysiology Clinics*, **2010**, 2, 587-598	1.4	2
76	Provokable left ventricular outflow tract obstruction in a patient without hypertrophy. *Nature Reviews Cardiology*, **2009**, 6, 313-6	14.8	2
75	Investigation and treatment of hypertrophic cardiomyopathy. *Clinical Medicine*, **2007**, 7, 383-7	1.9	2
74	Evident, but poorly defined: left ventricular hypertrabeculation/noncompaction and its diagnostic criteria: reply. *European Heart Journal*, **2005**, 26, 1144-1145	9.5	2
73	No re-appraisal of non-compaction diagnostic criteria without considering neurological co-morbidity and genetic heterogeneity: reply. *European Heart Journal*, **2008**, 29, 951-952	9.5	2
72	The p.(Cys150Tyr) variant in CSRP3 is associated with late-onset hypertrophic cardiomyopathy in heterozygous individuals. *European Journal of Medical Genetics*, **2020**, 63, 104079	2.6	2
71	The European Heart Journal: leading the fight to reduce the global burden of cardiovascular disease. *European Heart Journal*, **2020**, 41, 3113-3116	9.5	2
70	Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
69	Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. *Molecular Genetics and Metabolism*, **2021**, 132, 234-243	3.7	2
68	Iterative Reanalysis of Hypertrophic Cardiomyopathy Exome Data Reveals Causative Pathogenic Mitochondrial DNA Variants. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003388	5.2	2
67	Maximal Wall Thickness Measurement in Hypertrophic Cardiomyopathy: Biomarker Variability and its Impact on Clinical Care. *JACC: Cardiovascular Imaging*, **2021**, 14, 2123-2134	8.4	2
66	The genetic architecture of Plakophilin 2 cardiomyopathy. *Genetics in Medicine*, **2021**, 23, 1961-1968	8.1	2
65	Current use of cardiac magnetic resonance in tertiary referral centres for the diagnosis of cardiomyopathy: the ESC EORP Cardiomyopathy/Myocarditis Registry. *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 781-789	4.1	2
64	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. *PLoS ONE*, **2018**, 13, e0203078	3.7	2

63	Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers. *Journal of the American Heart Association*, **2021**, 10, e020227	6	2
62	The Safety and Feasibility of Transitioning From Transfemoral to Transradial Access Left Ventricular Endomyocardial Biopsy. *Journal of Invasive Cardiology*, **2020**, 32, E349-E354	0.7	2
61	Guía de práctica clínica de la ESC 2013 sobre estimulación cardiaca y terapia de resincronización cardiaca. *Revista Espanola De Cardiologia*, **2014**, 67, 58.e1-58.e60	1.5	1
60	126 Advanced Assessment of Cardiac Morphology and Prediction of Gene Carriage by CMR in Hypertrophic Cardiomyopathy - The HCMNET/UCL Collaboration. *Heart*, **2014**, 100, A72-A73	5.1	1
59	B Embryogenesis of Ventricular Myocardial Trabeculae Novel Insights from Episcopic 3D Imaging and Fractal Analysis of Wild-type and Notch MIB1 Noncompaction Mouse Models. *Heart*, **2014**, 100, A125-A128	5.1	1
58	Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy. *Revista Espanola De Cardiologia (English Ed)*, **2012**, 65, 599-605	0.7	1
57	Time for education in cardiogenetics. *Neurology International*, **2011**, 1, 2	0	1
56	Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. *Heart*, **2011**, 97, 1914-9	5.1	1
55	A case of necrotizing myopathy with proximal weakness and cardiomyopathy. *Neurology*, **2012**, 78, 1527-33	8.3	1
54	Relevance of platelet activation in obstructive hypertrophic cardiomyopathy. *Heart*, **2008**, 94, 688-9	5.1	1
53	The new European definition of cardiomyopathies: which space for muscle dystrophies?: reply. *European Heart Journal*, **2008**, 29, 1592-1592	9.5	1
52	Cardiac resynchronization therapy: the procedure and progress so far. *British Journal of Hospital Medicine (London, England: 2005)*, **2005**, 66, 469-73	0.8	1
51	Management strategies in hypertrophic cardiomyopathy: influence of age and morphology. *European Heart Journal Supplements*, **2001**, 3, L10-L14	1.5	1
50	Diseases of the Myocardium and Endocardium **2012**, 318-333		1
49	Tafamidis for the treatment of transthyretin amyloidosis. *Future Cardiology*, **2019**, 15, 53-61	1.3	1
48	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology-Cardiovascular Round Table. *Cardiovascular Research*, **2021**, 117, 1248-1256	9.9	1
47	The genetics of left ventricular noncompaction. *Current Opinion in Cardiology*, **2021**, 36, 301-308	2.1	1
46	Cardiomyopathies in children: Mitochondrial and storage disease. *Progress in Pediatric Cardiology*, **2018**, 51, 16-23	0.4	1

45	A Normal Electrocardiogram Does Not Exclude Infra-Hisian Conduction Disease in Patients With Myotonic Dystrophy Type 1. *JACC: Clinical Electrophysiology*, **2021**, 7, 1038-1048	4.6	1
44	Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy.. *Journal of the American College of Cardiology*, **2022**, 79, 1986-1997	15.1	1
43	The collapsing pulse. *British Journal of Hospital Medicine (London, England: 2005)*, **2012**, 73, C78-80	0.8	0
42	Cardiac manifestations of McArdle disease. *European Heart Journal*, **2019**, 40, 397-398	9.5	0
41	Prospective follow-up in various subtypes of cardiomyopathies: insights from the ESC EORP Cardiomyopathy Registry. *European Heart Journal Quality of Care & Clinical Outcomes*, **2021**, 7, 134-142	4.6	0
40	Prevalence of Hypertrophic Cardiomyopathy in the UK Biobank Population. *JAMA Cardiology*, **2021**, 6, 852-854	16.2	0
39	Relationship Between Maximal Left Ventricular Wall Thickness and Sudden Cardiac Death in Childhood Onset Hypertrophic Cardiomyopathy.. *Circulation: Arrhythmia and Electrophysiology*, **2022**, CIRCEP121010075	6.4	0
38	Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. *Molecular Genetics and Metabolism Reports*, **2019**, 20, 100493	1.8	
37	Hypertrophic Cardiomyopathy-Need for Gene-Specific Treatment?-Reply. *JAMA Cardiology*, **2019**, 4, 831-832	16.2	
36	Reply: Revisiting Genome Sequencing Data in Light of Novel Disease Gene Associations. *Journal of the American College of Cardiology*, **2019**, 73, 1366-1367	15.1	
35	Almanac 2014: Cardiomyopathies.. *Cardiologia Croatica*, **2015**, 9, 543-557	0	
34	Concerns About the HCM Risk-Kids Study-Reply. *JAMA Cardiology*, **2020**, 5, 363-364	16.2	
33	123 The Development of a Dietary Preparation Protocol for Optimal Inflammatory Imaging Using 18F-FDG PET. *Heart*, **2016**, 102, A87.1-A87	5.1	
32	122 Introduction of Stress Only Myocardial Perfusion Scintigraphy: A Quality Improvement Programme. *Heart*, **2016**, 102, A86.2-A87	5.1	
31	153 Novel Insights into the Pathophysiology of Hypertrophic Cardiomyopathy Using Label free Quantitative Proteomics. *Heart*, **2014**, 100, A89-A90	5.1	
30	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. *Egyptian Heart Journal*, **2012**, 64, 17-24	1.3	
29	101 Ethnic Variation in Hypertrophic Cardiomyopathy. *Heart*, **2015**, 101, A58.1-A58	5.1	
28	Almanac 2014: cardiomyopathies. *Cor Et Vasa*, **2015**, 57, e28-e38	0.3	

27	88 Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy. *Heart*, **2014**, 100, A50.3-A51	5.1
26	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. *Revista Portuguesa De Cardiologia (English Edition)*, **2012**, 31, 255-261	0
25	Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. *Revista Portuguesa De Cardiologia*, **2012**, 31, 255-61	1
24	Cardiac manifestations of mitochondrial disorders: reply. *European Journal of Heart Failure*, **2010**, 12, 637-638	12.3
23	The quest for perfection: the contribution of the electrocardiogram to the prevention of sudden death in hypertrophic cardiomyopathy. *Europace*, **2009**, 11, 548-9	3.9
22	092 Interstitial expansion in health and disease□n equilibrium contrast CMR study. *Heart*, **2012**, 98, A53-A54	5.1
21	073 Evaluation of clinical markers of early disease expression and the ability to predict genotype in families with HCM and mutations in cardiac myosin binding protein C. *Heart*, **2012**, 98, A41.2-A42	5.1
20	061 Metabolic alteration in hypertrophic cardiomyopathy (METAL-HCM Study): randomised double blinded placebo controlled trial of perhexiline therapy in patient with hypertrophic cardiomyopathy. *Heart*, **2010**, 96, A36.2-A36	5.1
19	G.P.5.09 Severe necrotising myopathy and cardiomyopathy with anti-signal recognition peptide antibodies. *Neuromuscular Disorders*, **2008**, 18, 771-772	2.9
18	Treatment for heart failure: good news and bad. *British Journal of Hospital Medicine (London, England: 2005)*, **2005**, 66, 102-5	0.8
17	Alcoholic cardiomyopathy. *Drug Discovery Today: Disease Models*, **2005**, 2, 227-231	1.3
16	Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies **2018**, 259-317	
15	Risk Stratification in Patients with Hypertrophic Cardiomyopathy. *Developments in Cardiovascular Medicine*, **1998**, 83-88	
14	Application of current diagnostic criteria for arrhythmogenic right ventricular cardiomyopathy in every day clinical practice. *Current Pharmaceutical Design*, **2015**, 21, 515-24	3.3
13	124 The Use of Next Generation Sequencing to Determine Genotype-Phenotype Correlations in Dilated Cardiomyopathy. *Heart*, **2016**, 102, A87.2-A88	5.1
12	Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. *Acta Informatica Medica*, **2011**, 19, 235-40	1.9
11	The dilemma of an incidental preoperative electrocardiogram showing a Brugada phenotype. *BMJ Case Reports*, **2011**, 2011,	0.9
10	Cardiomyopathies the national society journals present selected research that has driven recent advances in clinical cardiology. *Srce I Krvni Sudovi*, **2012**, 31, 174-180	

9	Sudden Cardiac Death Risk Assessment **2019**, 145-155	
8	The Cardiomyopathies **2018**, 577-617	
7	Almanac 2011: cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. *Turk Kardiyoloji Dernegi Arsivi*, **2012**, 40, 76-84	
6	Almanac 2011: Cardiomyopathies. The national society journals present selected research that has driven recent advances in clinical cardiology. *Archivos De Cardiologia De Mexico*, **2012**, 82, 59-65	0.2
5	Reply: Myotonic Dystrophy and Conduction Disease.. *JACC: Clinical Electrophysiology*, **2021**, 7, 1625	4.6
4	Pathophysiology and Significance of Myocardial Ischemia in Hypertrophic Cardiomyopathy172-184	
3	Reversal of acute pulmonary oedema with beta-blockers in hypertrophic cardiomyopathy. *European Journal of Echocardiography*, **2003**, 4, 71-2	
2	Changing concepts in heart muscle disease: the evolving understanding of hypertrophic cardiomyopathy.. *Heart*, **2022**, 108, 768-773	5.1
1	Recommendations for addressing the translational gap between experimental and clinical research on amyloid diseases.. *Journal of Translational Medicine*, **2022**, 20, 213	8.5